Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Dossier - 20/12/2010 13209_de.jpg

    Environmental toxins: effect and origin

    Environmental toxins, also referred to as xenobiotics, are chemicals that do not occur in biological substance cycles; they are difficult to degrade and often have a toxic effect. Xenobiotic substances are becoming an increasing problem because we are constantly exposed to them and because they slowly but surely poison us. The World Health Organisation (WHO) sees xenobiotic substances as factors that contribute, along with other factors, to the…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/environmental-toxins-effect-and-origin
  • New edition - 24/05/2019 Magnetic resonance image of brain metastases.

    Tumour metastasis

    Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial – with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Article - 04/08/2009 09305_de.jpg

    Wilfried Weber recombines new cell constituents

    Prof. Dr. Wilfried Weber who was appointed professor of synthetic biology at the Centre for Biological Signalling Studies bioss at the University of Freiburg in May 2009 has always had a great interest in the practical application of biology. Weber and his team have a thorough understanding of how different parts of signalling networks can be reassembled for specific purposes for example switching off the antibiotic resistance of bacteria.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/wilfried-weber-recombines-new-cell-constituents
  • Article - 09/01/2009 07710_de.jpg

    Kay Diederichs – important insights in the fight against bacterial antibiotics resistance

    Bacteria will always find ways to defend themselves against substances such as antibiotics, thus inhibiting their effect. Many bacteria have pump systems that they use to actively remove antibiotic drugs from the cell. Prof. Kay Diederichs at the University of Constance is working on the elucidation of these mechanisms in order to produce useful information for the development of bacterial pump inhibitors.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/kay-diederichs-important-insights-in-the-fight-against-bacterial-antibiotics-resistance
  • Article - 18/02/2009 Portrait of Prof. Andreas Trumpp

    Dormant stem cells can be awakened with interferon alpha

    With a number of new papers published in renowned scientific journals Prof. Dr. Andreas Trumpp has been able to further cement his outstanding reputation as one of the world leaders in stem cell research. Trumpp who has been professor and head of the Department of Cell Biology at the German Cancer Research Centre DKFZ since summer 2008 also became head of the newly founded Heidelberg Institute for Stem Cell Technology and Experimental Medicine…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/dormant-stem-cells-can-be-awakened-with-interferon-alpha
  • Article - 04/07/2011 14640_de.jpg

    The adhesion of cells to the endothelium and to artificial surfaces

    Professor Stefan W. Schneider from the Mannheim Medical Faculty is investigating the function of the vascular endothelium and its interaction with blood and tumour cells using microfluidics methods that enable him to measure the adhesion of cells to the walls of blood vessels under physiological flow conditions. As part of an interdisciplinary project, he is investigating the characteristics of wafer-thin surfaces covered with living cells, which…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/the-adhesion-of-cells-to-the-endothelium-and-to-artificial-surfaces
  • Press release - 24/10/2011 15650_de.jpg

    Curetis AG Opens Unyvero™ Cartridge Production Facility

    Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, announced the opening of its state-of-the-art production facility for disposable Unyvero™ cartridges in Bodelshausen (near Tuebingen, Germany).

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-opens-unyvero-cartridge-production-facility
  • Press release - 18/09/2009

    Why don’t brain tumours respond to drugs?

    Malignant brain tumours do not often respond to promising new drugs. Researchers from Heidelberg have now uncovered a mechanism and a tumour marker that are linked to the development of this resistance. A “death receptor” might possibly indicate the chances of success of chemotherapy at the same time as providing new approaches for developing a new therapy for the successful treatment of brain tumours.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/why-don-t-brain-tumours-respond-to-drugs
  • Article - 23/01/2012 16231_de.jpg

    Karen Lienkamp: intelligent surface materials fight off microbes

    Resistant germs are tough and will settle anywhere. They grow on all types of surface which is a major cause for concern for medical doctors and industrial researchers alike. The chemist Dr. Karen Lienkamp Junior Fellow at the Freiburg Institute for Advanced Studies FRIAS and head of a group of junior researchers at the University of Freiburg develops surface materials for biomedical applications and industrial production facilities.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/karen-lienkamp-intelligent-surface-materials-fight-off-microbes
  • Article - 18/01/2018 Teaser-Mutationen-Primartumor.png

    Medications that target metastasing tumours

    Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/medications-that-target-metastasing-tumours
  • Article - 20/01/2020 Bild_1.jpg

    Brain tumour patients could benefit from heavy ion therapy

    Glioblastoma is a malignant brain tumour. It does not respond anywhere near as well to conventional forms of therapy than other tumours because it contains particularly resistant cancer cells. Scientists at the Heidelberg Ion Beam Therapy Center (HIT) at Heidelberg University Hospital and the German Cancer Research Center have shown that heavy ion therapy is effective against these cells.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/Brain-tumour-patients-could-benefit-from-heavy-ion-therapy
  • Dossier - 22/08/2011 Volcanic crater in the Yellowstone National Park: The lake is surrounded by an orange ring consisting of algae and bacteria which have become adapted to the extremely high temperatures.<br />

    Stress and molecular defence mechanisms

    Organisms can experience stress from exposure to bacteria and pathogenic fungi; in fact, stress can arise from exposure to any type of environmental influence. As they have evolved, biological cells have developed numerous molecular mechanisms that enable them to survive even in inhospitable conditions. What kind of effects do abiotic stress factors have on plants and human beings? How do cells protect themselves? Are researchers able to increase…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/stress-and-molecular-defence-mechanisms
  • Article - 27/11/2017 Petri dish with nine square dark blue platelets under blue light.

    Antimicrobial layer expected to fight hospital acquired infections

    Infections caused by bacteria that contaminate the surface of medical devices such as catheters and wound dressings are not that rare and can even be life-threatening. However, at present there is no really effective way to keep these products germ-free until they are used. Scientists at the University of Freiburg have now developed a surface coating that reliably kills bacteria, but is harmless to human cells.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/antimicrobial-layer-expected-to-fight-hospital-acquired-infections
  • Dossier - 23/07/2012 17728_de.jpg

    Extremophilic bacteria

    What causes stress for some, actually speeds others like extremophilic bacteria up. They love it hot, sour or salty, toxic substances like heavy metals also do them good and even give them energy. As molecular and systems biology techniques get better and better, industry is also becoming increasingly interested in these exotic organisms. What potential does knowing the biochemistry of extremophilic bacteria have for the pharmaceutical, cosmetics…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/extremophilic-bacteria
  • Article - 03/10/2010 12438_de.jpg

    ColepCCL: A creative hub to prepare for the company’s move into the life sciences

    ColepCCL Rapid-Spray a ColepCLL subsidiary based in Laupheim Germany has made a name for itself as the largest European contract filler of aerosols. However ColepCLL which employs around 3500 people in five countries is now planning to open up new fields of activity in the life sciences area.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/colepccl-a-creative-hub-to-prepare-for-the-company-s-move-into-the-life-sciences
  • Press release - 14/01/2009 07820_de.jpg

    Hunters of lost treasures

    On 1st December 2008 Prof. Dr. Karl Schmid the first person to hold the F.W. Schnell Foundations endowed professorship for crop biodiversity and breeding informatics started the ball rolling on a unique European-wide project. Schmid and his colleagues are searching gigantic databases in which genetic analyses and plant descriptions are stored for hidden treasures.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/hunters-of-lost-treasures
  • Article - 03/11/2014 Photo of Prof. Jucker browsing through a journal.

    Dementia and the prion principle

    Prions are misfolded proteins that are associated with diseases such as BSE, Creutzfeldt-Jakob disease and scrapie. What makes prions particularly dangerous is their ability to induce properly folded proteins to convert into misfolded prion forms. This principle seems to be more widespread than previously thought. Dr. Mathias Jucker from the University of Tübingen and his American colleague Lary Walker from Emory University have put forward a…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/dementia-and-the-prion-principle
  • Article - 09/08/2010 10264_de.jpg

    Elara Pharmaceuticals

    The Heidelberg-based biotech company ELARA Pharmaceuticals is focused on the development of treatments of tumours through the inhibition of the hypoxia signalling pathway (HIF) and through the induction of apoptosis. The company’s lead candidate targets multiple myeloma, a cancer that arises in the plasma cells of the immune system.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/elara-pharmaceuticals
  • Funding

    Future Insight Prize

    Funding programme, Funded by: Merck KGaA, Submission deadline: 31/12/2021
    https:////www.gesundheitsindustrie-bw.de/en/database/funding/future-insight-prize
  • Article - 05/11/2009 10032_de.jpg

    The abatement of phytopathological fungi

    In the past, fungal infestation of agricultural crops has been known to affect the fate of entire nations, and nowadays it still continues to pose a threat to the world’s food supply. There is huge need for the development of new environmentally friendly agricultural fungicides, as fungi are fast becoming resistant to standard fungicides. Scientists are concentrating on the use of fungus-derived natural substances as the specific targets of…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/the-abatement-of-phytopathological-fungi
  • Article - 30/01/2012 16256_de.jpg

    Silicone application in medical technology

    Silicone is flexible, biocompatible and heat-resistant, characteristics that make organosilicone compounds ideal for a wide range of applications in medical technology. Up until now, the broad application of such compounds has been hampered chiefly by the high surface friction of silicone. The Reutlingen-based company Silcos GmbH has developed special methods for the treatment of surfaces that considerably improve the compound's range of…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/silicone-application-in-medical-technology
  • Press release - 30/03/2011 14044_de.jpg

    Bacteria poison themselves from within

    The research group led by Anton Meinhart at the Max Planck Institute for Medical Research in Heidelberg has shown that proteins from the zeta toxin group trigger a self-destructive mechanism in bacteria. The triggers for this bacterial suicide are toxin/antitoxin systems that play an important role in the hereditary transmission of resistance and virulence genes. The scientists have thus found a valuable new tool for the development of new…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/bacteria-poison-themselves-from-within
  • Article - 12/07/2010 11759_de.jpg

    TET Systems: Controlled gene expression in eukaryotes

    The most common and most successful system used for the experimental regulation of gene expression in eukaryotes is based on a gene switch that regulates the resistance of bacteria to tetracycline. The Tet technology also provides researchers with a tool that enables them to specifically, quantitatively and reversibly control the activity of individual genes in vivo and in vitro. The Heidelberg-based company TET Systems sells licences for the Tet…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/tet-systems-controlled-gene-expression-in-eukaryotes
  • Article - 19/07/2016 Symbolic 3D model with a T cell equipped with CAR and the relevant DNA.

    Licence to kill – the enormous potential of CAR T cells

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/licence-to-kill-the-enormous-potential-of-car-t-cells

Page 4 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search